MGNXNasdaqPharmaceutical PreparationsFiscal year ends December 31
MACROGENICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$3.33+0.08 (+2.46%)
Close on Oct 19, 2026
- Market cap
- $211.77M
- P/E (TTM)
- –
- Dividend yield
- –
MACROGENICS INC revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaborative and other agreements | $25.49M | $570.00K | $20.27M | $53.00M | $5.56M | $6.60M | $14.74M | $101.41M | $2.16M | $1.61M | $6.52M | $895.00K | 77.6% | +358.6% |
| Royalty revenue | $7.34M | $6.15M | – | – | $1.31M | $442.00K | – | – | $98.00K | $160.00K | $0 | $10.00K | 22.4% | +460.2% |
| Revenue from government agreements | – | – | – | – | – | – | – | – | $493.00K | $358.00K | $462.00K | $345.00K | – | – |
| Product sales, net | – | – | $0 | $0 | $0 | $0 | $2.16M | $4.16M | $5.25M | $4.86M | $4.69M | $4.70M | – | – |
| Contract manufacturing | – | $14.05M | $11.27M | $19.84M | $15.37M | $6.15M | $3.32M | $4.57M | $2.89M | $2.28M | $169.00K | $4.46M | – | – |
| Government agreements | – | – | – | $0 | $0 | $0 | – | $566.00K | $493.00K | $358.00K | – | $345.00K | – | – |
By region
From the segment and revenue-disaggregation notes of Macrogenics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.